Evidence map›Paper›PMID 35454013›Full record

ReviewDiagnostics (Basel, Switzerland)2022

The Need for Standardization in Next-Generation Sequencing Studies for Classic Hodgkin Lymphoma: A Systematic Review.

Antonio Santisteban-Espejo, Irene Bernal-Florindo, Jose Perez-Requena, Lidia Atienza-Cuevas, Julia Moran-Sanchez, María Del Carmen Fernandez-Valle, Raquel Romero-Garcia, Marcial Garcia-Rojo

Open access · goldAbstract readReview
In one paragraph

Review in Diagnostics (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.5field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Antonio Santisteban-EspejoDepartment of Pathology, Puerta del Mar University Hospital, 11009 Cadiz, Spain.
Irene Bernal-FlorindoInstitute of Research and Innovation in Biomedical Sciences of the Province of Cadiz (INiBICA), 11009 Cadiz, Spain.
Jose Perez-RequenaDepartment of Pathology, Puerta del Mar University Hospital, 11009 Cadiz, Spain.
Lidia Atienza-CuevasDepartment of Pathology, Puerta del Mar University Hospital, 11009 Cadiz, Spain.
Julia Moran-SanchezDepartment of Medicine, Faculty of Medicine, University of Cadiz, 11003 Cadiz, Spain.
María Del Carmen Fernandez-ValleDepartment of Hematology and Hemotherapy, Puerta del Mar University Hospital, 11009 Cadiz, Spain.
Raquel Romero-GarciaInstitute of Research and Innovation in Biomedical Sciences of the Province of Cadiz (INiBICA), 11009 Cadiz, Spain.ORCID 0000-0001-9851-0487
Marcial Garcia-RojoDepartment of Pathology, Puerta del Mar University Hospital, 11009 Cadiz, Spain.ORCID 0000-0001-6272-9401
Biomedical Research and Innovation Institute of Cadiz · ESHospital Universitario Puerta del Mar · ESUniversidad de Cádiz · ES

Funding

Andalusian Health Service RH-0145-2020EU FEDER ITI for Cadiz Province PI-0032-2017
6 · The paper itself

Abstract

Classic Hodgkin lymphoma (cHL) constitutes a B cell-derived neoplasm defined by a scarce tumoral population, termed Hodgkin and Reed-Sternberg (HRS) cells, submerged into a histologically heterogeneous microenvironment. The paucity of HRS cells has historically hampered genetic studies, rendering the identification of the recurrent genetic lesions and molecular pathways deregulated in this lymphoma difficult. The advent of high-throughput sequencing methods such as next-generation sequencing (NGS) could sensibly optimize the identification of the mutational landscape of cHL. However, there is no current consensus either in the design of panels for targeted NGS or in its most relevant clinical applications. In this work, we systematically review the current state of NGS studies of cHL, stressing the need for standardization both in the candidate genes to be analyzed and the bioinformatic pipelines. As different institutions have developed and implemented their own customized NGS-based protocols, to compare and systematically review the major findings of this ongoing research area could be of added value for centers that routinely perform diagnostic, monitoring and genotyping strategies in cHL samples. The results of this systematic review should contribute to the interdepartmental harmonization and achievement of a consensus in the current clinical applications of NGS studies of cHL.

Indexed as

Classic Hodgkin lymphomaliquid biopsynext-generation sequencingstandardization

Identifiers

PMID35454013
PMCPMC9027849
OpenAlexW4223456130

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.